Drug Profile
DAPH 1
Alternative Names: CGP 52411Latest Information Update: 17 Aug 2001
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Aug 2001 No-Development-Reported for Cancer in Switzerland (Unknown route)
- 23 Jul 1998 Profile reviewed
- 11 Apr 1995 Preclinical development for Cancer in Switzerland (Unknown route)